Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

YDES

YD Bio Ltd

May 01 • 04:00PM ET

4.80

-0.30 -5.88 %

Healthcare • Biotechnology • Taiwan • Small • NASD

Apr 30, 6:05 PMYD Bio posts 17% revenue growth to $596,817 in 2025 as net loss widens to $8.3 million

Held by: ONEQ

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.99	Insider Own	80.69%	Shs Outstand	70.52M	Perf Week	-12.09%
Market Cap	338.50M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	13.62M	Perf Month	-34.16%
Enterprise Value	338.49M	PEG	-	EPS next Q	-	Inst Own	0.20%	Short Float	0.17%	Perf Quarter	-59.56%
Income	-2.97M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.97	Perf Half Y	-63.75%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-43.61%	Short Interest	0.02M	Perf YTD	-60.62%
Book/sh	-4.77	P/C	33850.00	EPS next 5Y	-	ROE	-	52W High	25.00 -80.80%	Perf Year	-58.97%
Cash/sh	0.00	P/FCF	-	EPS past 3/5Y	- 6.41%	ROIC	-	52W Low	5.00 -4.00%	Perf 3Y	-54.95%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.07% 10.12%	Perf 5Y	-52.19%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	14.61%	Oper. Margin	-	ATR (14)	0.54	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.02	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	30.94	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	0.02	EPS Q/Q	-116.03%	SMA20	-14.10%	Beta	-0.31	Target Price	-
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-29.88%	Rel Volume	0.17	Prev Close	5.10
Employees	15	LT Debt/Eq	-	Earnings	-	SMA200	-58.65%	Avg Volume	23.64K	Price	4.80
IPO	Dec 23, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	3,986	Change	-5.88%

Apr-30-26 06:00PM	YD Bio Limited Reports Full Year 2025 Financial Results (GlobeNewswire) -5.88%
Mar-31-26 08:00AM	YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States (GlobeNewswire)
Mar-17-26 08:00AM	YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem (GlobeNewswire) -8.55%
Feb-25-26 08:00AM	YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform (GlobeNewswire)
Jan-29-26 08:30AM	YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy (GlobeNewswire) -9.89%
09:00AM	Loading…
Jan-06-26 09:00AM	YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation-Driven AI Platforms for Cancer Diagnostics and Drug Development (GlobeNewswire) -8.04%
Jan-05-26 09:00AM	YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap (GlobeNewswire) +5.67%
Dec-16-25 09:00AM	YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center (GlobeNewswire)
Dec-09-25 09:00AM	YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN (GlobeNewswire) -18.42%
Dec-02-25 09:00AM	YD Bio Limited Expands OkaiDx Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection (GlobeNewswire)
Nov-24-25 09:00AM	YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics (GlobeNewswire)
Nov-05-25 08:30AM	YD Bio and EG BioMed Expand U.S. Access to OkaiDx, a cfDNA-Methylation Blood Test for Post-Treatment Breast Cancer Monitoring (GlobeNewswire)
Oct-20-25 10:20AM	YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES (GlobeNewswire)
Oct-10-25 08:37AM	YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities (GlobeNewswire) -6.95%
Aug-29-25 07:30AM	YD Bio Limited Announces Closing of Business Combination and Listing on the Nasdaq Global Market (PR Newswire) +135.85%

YD Bio Ltd. is a biotechnology company building an integrated healthcare platform across regulated diagnostics, clinical services, and commercial healthcare markets. It operates DNA methylation-based oncology testing programs under an LDT-first strategy and provides compliant life science distribution and clinical trial supply chain services to pharmaceutical and biotechnology partners. The company's offerings include cancer detection products, regenerative ophthalmology solutions, and exosome-based technologies. YD Bio was founded on February 6, 2024 and is headquartered in Taipei, Taiwan.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

YDES

YD Bio Ltd

Upgrade your Finviz experience